Floatz logo

Individualized Anti-Tumor New Antigen Ineo-Vac-R01

Pancreatic Cancer Resectable

Zhejiang UniversityvaccinePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

189 Active assets in the Pancreatic Cancer Resectable cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

Individualized Anti-Tumor New Antigen Ineo-Vac-R01 is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →